Literature DB >> 20463660

A comprehensive hepatitis C viral kinetic model explaining cure.

E Snoeck1, P Chanu, M Lavielle, P Jacqmin, E N Jonsson, K Jorga, T Goggin, J Grippo, N L Jumbe, N Frey.   

Abstract

We propose a model that characterizes and links the complexity and diversity of clinically observed hepatitis C viral kinetics to sustained virologic response (SVR)-the primary clinical end point of hepatitis C treatment, defined as an undetectable viral load at 24 weeks after completion of treatment)-in patients with chronic hepatitis C (CHC) who have received treatment with peginterferon alpha-2a +/- ribavirin. The new attributes of our hepatitis C viral kinetic model are (i) the implementation of a cure/viral eradication boundary, (ii) employment of all hepatitis C virus (HCV) RNA measurements, including those below the lower limit of quantification (LLOQ), and (iii) implementation of a population modeling approach. The model demonstrated excellent positive (99.3%) and negative (97.1%) predictive values for SVR as well as high sensitivity (96.6%) and specificity (99.4%). The proposed viral kinetic model provides a framework for mechanistic exploration of treatment outcome and permits evaluation of alternative CHC treatment options with the ultimate aim of developing and testing hypotheses for personalizing treatments in this disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20463660     DOI: 10.1038/clpt.2010.35

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  59 in total

1.  Hepatocyte proliferation and hepatitis C virus kinetics during treatment.

Authors:  H Dahari; L Rong; T J Layden; S J Cotler
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies.

Authors:  Eric L Haseltine; Holly Kimko; Haobin Luo; John Tolsma; Doug J Bartels; Tara L Kieffer; Varun Garg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-20       Impact factor: 2.745

3.  A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor.

Authors:  Laetitia Canini; Annabelle Lemenuel-Diot; Barbara J Brennan; Patrick F Smith; Alan S Perelson
Journal:  Antivir Ther       Date:  2018

Review 4.  A New Model for the Dynamics of Hepatitis C Infection: Derivation, Analysis and Implications.

Authors:  Philip J Aston
Journal:  Viruses       Date:  2018-04-13       Impact factor: 5.048

5.  HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Authors:  Harel Dahari; Laetitia Canini; Frederik Graw; Susan L Uprichard; Evaldo S A Araújo; Guillaume Penaranda; Emilie Coquet; Laurent Chiche; Aurelie Riso; Christophe Renou; Marc Bourliere; Scott J Cotler; Philippe Halfon
Journal:  J Hepatol       Date:  2016-02-22       Impact factor: 25.083

6.  A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression.

Authors:  Mohamed A Kamal; Ronald Gieschke; Annabelle Lemenuel-Diot; Catherine A A Beauchemin; Patrick F Smith; Craig R Rayner
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

Review 7.  Applications of mechanistic modelling to clinical and experimental immunology: an emerging technology to accelerate immunotherapeutic discovery and development.

Authors:  L V Brown; E A Gaffney; J Wagg; M C Coles
Journal:  Clin Exp Immunol       Date:  2018-09       Impact factor: 4.330

8.  Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics.

Authors:  Vladimir Reinharz; Harel Dahari; Danny Barash
Journal:  Math Biosci       Date:  2018-03-15       Impact factor: 2.144

9.  Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling.

Authors:  Libin Rong; Jeremie Guedj; Harel Dahari; Alan S Perelson
Journal:  Antivir Ther       Date:  2014-01-16

10.  Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Authors:  Jeremie Guedj; Yaron Rotman; Scott J Cotler; Christopher Koh; Peter Schmid; Jeff Albrecht; Vanessa Haynes-Williams; T Jake Liang; Jay H Hoofnagle; Theo Heller; Harel Dahari
Journal:  Hepatology       Date:  2014-10-27       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.